Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives
M Devabhaktuni, S Bangalore - Vascular health and risk …, 2009 - Taylor & Francis
Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular
risk factors which together cause an increase in coronary heart disease-related events that …
risk factors which together cause an increase in coronary heart disease-related events that …
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia
K McKeage, MAA Siddiqui - American journal of cardiovascular drugs, 2008 - Springer
Amlodipine/atorvastatin (Caduet®) is a once-daily fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease
MP Curran - Drugs, 2010 - Springer
Amlodipine/atorvastatin (Caduet®) is a single-tablet, fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease
WH Frishman, AL Zuckerman - Expert Review of Cardiovascular …, 2004 - Taylor & Francis
In 2002, the World Health Organization estimated that over 58% of cardiovascular disease in
North America is due to 'both blood pressure and cholesterol higher than optimal' …
North America is due to 'both blood pressure and cholesterol higher than optimal' …
Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination
F Aslam, A Haque, V Lee, JA Foody - Patient preference and …, 2009 - Taylor & Francis
Cardiovascular disease (CVD) accounts for in excess of 930,000 deaths in the United States
each year. Risk factors for CVD often co-exist. Studies estimate that over half of the …
each year. Risk factors for CVD often co-exist. Studies estimate that over half of the …
A single-pill combination of amlodipine besylate and atorvastatin calcium (update).
R Blank, FD Hobbs, J Zamorano… - Drugs of Today …, 2007 - europepmc.org
This review describes the clinical profile and rationale for the development of a single-pill
formulation of the calcium channel blocker amlodipine besylate, a blood-pressure--lowering …
formulation of the calcium channel blocker amlodipine besylate, a blood-pressure--lowering …
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single‐pill therapy
MR Cowie - International journal of clinical practice, 2005 - Wiley Online Library
Single‐pill amlodipine besylate/atorvastatin calcium (Caduet®, Pfizer Inc, NY, USA) is the
first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia …
first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia …
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial
FH Messerli, GL Bakris, RD Ferrera… - The Journal of …, 2006 - Wiley Online Library
The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an …
FDR Hobbs, G Gensini, GBJ Mancini… - International journal of …, 2006 - Elsevier
BACKGROUND: In order to prevent cardiovascular events, it is essential to effectively
manage overall risk of cardiovascular disease. However, despite guideline …
manage overall risk of cardiovascular disease. However, despite guideline …
A randomized, placebo‐controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 …
RA Preston, P Harvey, O Herfert… - The Journal of …, 2007 - Wiley Online Library
Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …